LIMITATION OF MFARCT SIZE
Any intervention to limit the size of an evolving infarction must be performed within the first four to six hours of infarction, before cells become irreversibly necrotic. The most promising techniques involve early reperfusion, i.e., fibrinolysis (e.g., streptokinase), coronary angioplasty, or surgery within the first four to six hours after infarction.
Most patients with acute transmural myocardial infarction have complete obstruction of a coronary artery due to thrombosis that can be documented safely with coronary arteriography within the first four hours of infarction. Administration of intracoronary streptokinase to lyse clots by activating plasminogen opens the coronary artery in 70 to 80 per cent of these patients (somewhat lower if intravenous streptokinase is employed) (Fig. 7-3). Electrocardiographic evidence of infarction usually still evolves. The time course of cardiac enzyme elevation is accelerated, thought to be evidence of washout of enzymes from the heart by reperfusion. Thus, even though this technique does not prevent infarction, it may salvage a portion of the myocardium in jeopardy. There is usually a highgrade stenosis in the area of thrombosis that can be dilated acutely with coronary angioplasty at the time of streptokinase infusion or approached with angioplasty or surgery at a later date to prevent reocclusion. Long-term results and potential complications (e.g., intra-myocardial hemorrhage) are still being determined. Both intracoronary and intravenous streptokinase have profound systemic fibrinolytic effects, and massive bleeding may occur from arterial puncture sites or surgical wounds.
The role of angioplasty during acute myocardial infarction either with or without streptokinase administration is also under investigation. Even though early surgical revascularization is possible after myocardial infarction, it is logistically difficult to perform within the first four to six hours after the onset of chest pain and has not been demonstrated definitively to limit infarct size.
- TREATMENT
- Clinical Manifestations
- C. MALABSORPTION
- ACUTE AND CHRONIC HEPATITIS - DEFIRILTIORI
- MULTISYSTEM DISEASE WITH RENAL INVOLVEMENT
- CARCINOMA OF THE PANCREAS - Clinical Manifestations
- PATHOPHYSIOLOGY OF AIRWAY OBSTRUCTION
- PERICARDIAL DISEASES - ACUTE PERICARDITIS
- Sigmoidoscopy and Colonoscopy
- Peutz-Jeghers Syndrome
- ARTERIOSCLEROSIS OBLITERANS
- DC CARDIOVERSION AND DEFIBRILLATION
- Membranous Glomerulopathy
- CLASSIFICATION AND PATHOPHYSIOLOGY
- PHYSIOLOGY OF THE SYSTEMIC CIRCULATION
- Factors Involved in the Choice of Type of Dialysis
- NONPHARMACOLOGICAL THERAPY OF TACHYARRHYTHMIAS
- LABORATORY TESTS IN LIVER DISEASE
- PHYSICAL EXAMINATION
- Blood Chemistries
- RHEUMATIC FEVER
- CLINICAL MANIFESTATIONS OF ENDSTAGE RENAL DISEASE
- Uremic Osteodystrophy
- Endoscopic “Retrograde” Cholangiopancreatography (ERCP)
- NONPENETRATING TRAUMA
- History and Physical Examination
- TUMORS OF THE PLEURAL SPACE
- CLINICAL PRESENTATION
- CARDIAC TUMORS
- PLEURAL EFFUSIONS
- Bartter’s Syndrome
- THE APPROACH TO THE PATIENT WITH GASTROINTESTINAL HEMORRHAGE
- Portal Hypertension
- Texas MedicareRX
- ANGINA PECTORIS